• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 5 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 7 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 8 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 8 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 8 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 9 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 9 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 9 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 9 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    • Mashup Score: 5
      Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803 - 10 month(s) ago

      Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD 1, Antje Hoering, PhD 2, Parameswaran Hari, MBBS, MD 3, Rachael Sexton, PhD 2 * and Robert Z. Orlowski, MD, PhD 4 1 City of Hope Medical Center, Duarte, CA 2 SWOG Statistical Center, Seattle, WA 3 Division of Hematology and Oncology, Department of Medicine, Medical College of

      Source: ash.confex.com
      Categories: General Medicine News, Hem/Oncs
      Tweet Tweets with this article
      • Profile photo of 	mtmdphd
        mtmdphd

        . @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/zV0OvcDZWf

    Load More
    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings